HC Wainwright Issues Optimistic Outlook for NAGE Earnings

Key Points

• HC Wainwright has revised its Q2 2026 earnings per share estimate for Niagen Bioscience to $0.09, up from $0.08, and maintains a "Buy" rating with a price target of $12.00.
• Niagen Bioscience reported $0.04 earnings per share for the most recent quarter, surpassing analysts' expectations of $0.02, with revenues of $31.12 million against an estimate of $28.55 million.
• Institutional investors have increased their stakes in Niagen Bioscience, with hedge funds collectively owning 15.41% of the company's stock.

Niagen Bioscience, Inc. (NASDAQ:NAGE - Free Report) - Investment analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for shares of Niagen Bioscience in a research report issued to clients and investors on Monday, August 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.09 for the quarter, up from their previous estimate of $0.08. HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. HC Wainwright also issued estimates for Niagen Bioscience's Q3 2026 earnings at $0.11 EPS and FY2026 earnings at $0.40 EPS.

A number of other equities research analysts have also weighed in on the company. Wall Street Zen lowered Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 2nd. Canaccord Genuity Group lifted their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Finally, Roth Capital reiterated a "buy" rating and issued a $23.00 target price (up previously from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $13.42.

Niagen Bioscience Stock Up 1.2%

Shares of NASDAQ NAGE opened at $10.38 on Wednesday. Niagen Bioscience has a fifty-two week low of $2.94 and a fifty-two week high of $14.69. The business has a 50 day moving average price of $11.70 and a two-hundred day moving average price of $8.35. The firm has a market cap of $827.84 million, a PE ratio of 49.43 and a beta of 2.12.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%. The firm had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of NAGE. Geode Capital Management LLC grew its stake in Niagen Bioscience by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company's stock valued at $6,128,000 after purchasing an additional 5,186 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in Niagen Bioscience by 1,785.9% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company's stock valued at $5,365,000 after purchasing an additional 957,665 shares in the last quarter. Renaissance Technologies LLC grew its stake in Niagen Bioscience by 68.0% in the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company's stock valued at $3,781,000 after purchasing an additional 288,588 shares in the last quarter. Northern Trust Corp grew its stake in Niagen Bioscience by 13.8% in the fourth quarter. Northern Trust Corp now owns 429,873 shares of the company's stock valued at $2,280,000 after purchasing an additional 52,170 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its stake in Niagen Bioscience by 2.8% in the fourth quarter. JPMorgan Chase & Co. now owns 341,221 shares of the company's stock valued at $1,810,000 after purchasing an additional 9,305 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company's stock.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.